References
- Grayston J T, Kuo C C, Campbell L A, Wang S P. Chlamydia pneumoniae sp. nov. for Chlamydia sp. strain TWAR. Int J Systemic Bacteriol 1989; 39: 88–90
- Grayston J T, Campell L A, Wang S-P. A new respiratory tract pathogen: Chlamydia pneumoniae strain, TWAR. J Infect Dis 1990; 161: 618–25
- Kuo C C, Jackson L A, Campbell L A, Grayston J T. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev 1995; 8: 451–61
- Hammerschlag M R, Chirgwin K, Roblin P M, Gelling M, Dumornay W, Mandel L, Smith P, Schachter J. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis 1992; 14: 178–82
- Malinverni R, Kuo C-C, Campell L A, Lee A, Grayston J T. Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae Twar pneumonitis. Antimicrob Agents Chemother 1995; 39: 45–9
- Chirgwin K, Roblin P M, Hammerschlag M R. In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). Antimicrob Agents Chemother 1989; 33: 1634–5
- Cooper M A, Baldwin D, Matthews R S, Andrews J M, Wise R. In-vitro susceptibility of Chlamydia pneumoniae (TWAR) to seven antibiotics. J Antimicrob Chemother 1991; 28: 407–13
- Hammerschlag M R, Qumei K K, Roblin P M. In vitro activities of azithromycin, clarithromycin, l-ofloxacin and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992; 36: 1573–4
- Welsh L E, Gaydos C A, Quinn T C. In vitro evaluation of activities of azithromycin, erythromycin and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother 1992; 36: 291–4
- Agacfidan A, Moncada J, Schachter J. In vitro activity of Azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother 1993; 37: 1746–8
- Hammerschlag M R, Hyman C L, Roblin M. in vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992; 36: 682–3
- Fenelon L E, Mumatz G, Ridgway G L. The in-vitro susceptibility of Chlamydia pneumoniae. J Antimicrob Chemother 1990; 26: 763–7
- Hultén K, Cars O, Hjelm E, Engstrand L. In-vitro activity of azithromycin against intracellular Helicobacter pylori. J Antimicrob Chemother 1996; 37: 483–9
- Gladue R P, Bright G M, Isaacson R E, Newborg M F. In vitro and in vivo uptake of azithromycin (CP-62.993) by phagocytic cells; possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989; 33: 277–82
- Panteix G, Guillaumond B, Harf R, Desbos A, Sapin V, Leclercq M, Perrin-Fayolle M. In-vitro concentration of azithromycin in human phagocytic cells. J Antimicrob Chemother 1993; 31: 1–4, (Suppl E)
- Wyrick P B, Davis C D, Knight S T, Choong J. In-vitro activity of azithromycin on Chlamydia trachomatis infected polarized human endometrial epithelial cells. J Antimicrob Chemother 1993; 31: 139–50
- Gnarpe J, Eriksson K, Gnarpe H. In vitro activities of azithromycin and doxycycline against 15 islolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 1996; 40: 1843–5